Home Forums Melanoma Diagnosis: Stage IV Pondering the IPI/PD1 combination

  • This topic is empty.
Viewing 3 posts - 1 through 3 (of 3 total)
  • Author
    Posts
  • #22090
    Catherine Poole
    Keymaster

    So I’m thinking this morning what if the PD1 by Merck is approved very soon (October is the scheduled time) and doctors/patients decide to get both Yervoy (already approved) and combine with the Merck PD1 which has a slight edge on the BMS PD1. I’m sure there would be some wrangling with insurance, but seems like it a real possibility and may happen faster than the EAPs open for the combination. Any thoughts out there? I could be wrong, but doubt there would be any side affect profile that would be more worrisome. Just payment might be an issue.

    #64974
    RJoeyB
    Participant

    It’s an interesting thought, but wouldn’t the expected requirement of the initial approval to have already tried and failed ipi prior to getting pembro present a problem? I suppose an argument could be made that while the patient was refractory to ipi alone, now they want to try pembro plus ipi, but I know the insurance companies are a challenge when it comes to either maintenance doses or full-course retreatment with ipi. The definition of “failure” with ipi can be very vague, too. Is a partial response failure? I’ve heard arguments from medical professionals on both sides.

    Joe

    #64975
    Catherine Poole
    Keymaster

    I imagine there will be much off-label prescribing of PD1 and not requiring the failure of the IPI/ I just can’t imagine the FDA can ignore the combo movement. But the biggest hurdle will be insurance coverage.

Viewing 3 posts - 1 through 3 (of 3 total)
  • The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.